Status:
NOT_YET_RECRUITING
Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial
Lead Sponsor:
University of Florida
Collaborating Sponsors:
National Cancer Institute (NCI)
Patient-Centered Outcomes Research Institute
Conditions:
Human Papillomavirus (HPV) Vaccines
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low. The study team has developed an e...
Detailed Description
Human papillomavirus (HPV) vaccines have potential to prevent an average of 26,900 cancer cases each year in the United States, but vaccine coverage rates remain low. The study team has developed a he...
Eligibility Criteria
Inclusion
- Must be parent of an adolescent aged 11-12 years old.
- Providers working with age appropriate for study adolescents at the intervention clinics
- Adolescents/Parents/Providers willing to consent to participation
- Adolescents/Parents that can read and speak English
Exclusion
- Adolescents out of the age range for participation
- Adolescents/Parents/Providers unwilling to consent to participation
- Adolescents/Parents that can NOT read and speak English
Key Trial Info
Start Date :
September 15 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2027
Estimated Enrollment :
1296 Patients enrolled
Trial Details
Trial ID
NCT03429413
Start Date
September 15 2026
End Date
September 15 2027
Last Update
August 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32611